Peptides: The Science, Uses & Safety | Dr. Abud Bakri
A long Huberman Lab conversation with a physician on peptides with and without known receptors, covering BPC-157, thymic and pineal peptides, GHK-Cu, growth hormone secretagogues and GLP-1 drugs, with sourcing and legal caveats.
With Dr. Abud Bakri (Board-certified internal medicine physician)
Key moments
Tap a moment to play the video from there.
- 3:33Two kinds of peptidesBakri splits peptides into those with known receptors, like the GLP-1 drugs, and those without, like BPC-157 and TB-500. Huberman agrees this distinction is useful.
- 6:26Where BPC-157 came fromBakri describes the Croatian group that isolated BPC and the 15 amino acid fragment, and the early work on gastric juices that preceded it.
- 19:27Adverse events and human dataBakri says the lethal dose is unknown and that human data are limited to two small trials of enemas for ulcerative colitis, all from one group.
- 25:41Compounding and gray marketThey discuss compounded drugs, research-use-only sellers, raw materials sourced from China, and why batch quality varies.
- 41:17Angiogenesis and tumor concernHuberman asks whether BPC-157 could feed tumor growth. Bakri says no cancer signal appears in the preclinical literature but cautions that it comes from one group.
- 1:01:22Physician counsel and legal riskBakri explains how he would discuss unapproved peptides with a patient and why state boards and malpractice coverage make this risky.
- 1:07:37Pinealon and epithalonThey cover EDR (pinealon) and epithalon, Huberman's REM sleep experience, reported dosing, and the Russian research behind both.
- 1:29:39The thymus and its peptidesBakri explains thymic shrinkage with age, then covers thymosin alpha-1, TB-500 and thymulin, which depends on zinc.
- 2:03:53Growth hormone secretagoguesBakri describes tesamorelin, MK-677 and related compounds, with tradeoffs including insulin sensitivity, appetite and unresolved cancer questions.
- 2:41:55Retatrutide and drug patentsThey discuss how amino acid count affects patent length and compounding, and why this matters for retatrutide.
What the video says
Andrew Huberman interviews Dr. Abud Bakri, an internal medicine physician, about peptides. Bakri's central framing is that peptides fall into two groups: those with known receptors, such as the GLP-1 drugs, and those with no identified receptor, such as BPC-157 and TB-500. He argues the word "peptides" is too broad to be useful and that the two groups deserve different expectations.
The first hour centers on BPC-157. Bakri traces it to a Croatian group and to earlier work on gastric juices, and describes preclinical studies of tendon, gut and nervous system effects. He notes that nearly all the preclinical data come from one group, that its lethal dose has not been established, and that the human data amount to small early trials of rectal enemas for ulcerative colitis. He and Huberman discuss reports of worsening angiomas and hematomas, the theoretical concern about blood vessel growth and tumors, regulatory status, compounding pharmacies, telehealth, state medical boards and malpractice exposure. Bakri also describes a tricep injury he says healed quickly after local injections, which he presents as an anecdote.
The middle section covers the Russian bioregulator peptides pinealon (which they agree to call EDR) and epithalon, then the thymus: thymic shrinkage with age, thymosin alpha-1, TB-500, thymulin and zinc, and a simple blood count ratio Bakri says may reflect immune status. They also discuss GHK-Cu for skin, growth hormone secretagogues and their tradeoffs, and GLP-1 drugs including retatrutide, with attention to patents, compounding and long-term brain effects.
The episode includes sponsor reads and some tangents on lighting and pets. Most claims are the guest's own views or personal experience, and both speakers repeatedly say human trial data are thin.
On each compound
BPC-1576:26
Bakri describes BPC-157 as a 15 amino acid fragment of a larger protein, with preclinical studies on tendon, gut and nervous system effects. He says the human data are minimal, the lethal dose is unknown, and nearly all studies come from one Croatian group.
See how your DNA reads BPC-157TB-5001:38:18
Bakri describes thymosin beta-4 as a 43 amino acid peptide involved in the cell's actin skeleton and says it is used as a doping agent in horse racing. TB-500 is mentioned alongside BPC-157 as part of a combination people call the Wolverine stack.
See how your DNA reads TB-500Thymosin Alpha-11:32:15
Bakri says thymosin alpha-1 is a thymic peptide he describes as boosting T-cell activity. He says he injects 2.5 milligrams twice a week while traveling and did not get sick, which he offers as an anecdote.
See how your DNA reads Thymosin Alpha-1GHK-Cu1:50:33
Bakri describes GHK-Cu as a copper-bound tripeptide found in collagen, with most research coming from one lab. He says topical use has the best human data for skin and that injectable use is not FDA approved.
See how your DNA reads GHK-CuEpithalon1:19:57
Bakri links epithalon to the pineal gland and to Russian research reporting restored melatonin rhythms and lower mortality in a nursing home study. He flags that this evidence is Russian and not gold-standard research.
See how your DNA reads EpithalonTesamorelin2:03:53
Bakri says tesamorelin is FDA approved and gives a large growth hormone response, especially combined with a second secretagogue. He says IGF-1 can reach very high levels and that insulin sensitivity can worsen.
See how your DNA reads TesamorelinSemaglutide2:22:00
Bakri says semaglutide changed medicine for obesity and diabetes and that compounded versions grew out of shortages. He recounts his own bad reaction to a mislabeled pen and advises slow titration.
See how your DNA reads SemaglutideTirzepatide2:22:00
Bakri lists tirzepatide with semaglutide among the approved GLP-1 class drugs and mentions cash-pay prices dropping through direct programs.
See how your DNA reads TirzepatideRetatrutide2:33:55
Huberman predicts retatrutide will be a very large product. Bakri says its 39 amino acid length matters for patent classification and for whether pharmacies can compound it.
See how your DNA reads Retatrutide“We don't naturally make BPC157.”
What this video doesn’t settle
- Almost all BPC-157 preclinical data comes from one research group, and the human evidence is two small early trials, so effectiveness and safety in people remain unestablished.
- Bakri's tricep recovery, Huberman's REM changes and other personal accounts are single experiences with no control group.
- The longevity and immune findings for epithalon and thymic peptides come from Russian research that Bakri himself says is not gold-standard.
Questions this video answers
What does Dr. Abud Bakri say about BPC-157 safety?
Bakri says the lethal dose has never been established and that the human evidence is two small early trials of enemas for ulcerative colitis from one Croatian group. He reports no cancer signal in the preclinical literature but notes it all comes from that group.
Are research-use-only peptides reliable according to this video?
Bakri says quality varies and that buyers cannot know which products are good, with batch-to-batch differences. He recommends getting peptides through a physician rather than research websites.
What is the difference between peptides with and without known receptors?
Bakri says GLP-1 drugs act on known receptors and have strong clinical effects, while BPC-157 and TB-500 have no identified receptor. He argues the single word "peptides" hides this difference.
What does Bakri say about the thymus and immune health?
He says the thymus shrinks from puberty onward and links lower thymic function to higher disease risk. He mentions thymosin alpha-1, thymulin and zinc, and points to the lymphocyte to monocyte ratio on a routine blood count as a rough indicator.
Is BPC-157 legal in the United States according to this video?
Bakri says it is not FDA approved and its compounding status has been shifting between FDA categories. He adds that state medical boards may treat prescribing differently, and that sellers often label it for research use only.
Video by Andrew Huberman on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
